INT232486

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2008
Last Reported 2011
Negated 1
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 0.96
Pain Relevance 1.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Mtx1)
Anatomy Link Frequency
plasma 2
Mtx1 (Mus musculus)
Pain Link Frequency Relevance Heat
methotrexate 248 100.00 Very High Very High Very High
cINOD 18 97.00 Very High Very High Very High
Arthritis 115 90.72 High High
rheumatoid arthritis 51 75.68 Quite High
Infliximab 33 71.44 Quite High
Etanercept 46 69.72 Quite High
Adalimumab 41 68.12 Quite High
aspirin 2 41.76 Quite Low
Pain 33 17.52 Low Low
Leflunomide 3 6.08 Low Low
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 86 95.40 Very High Very High Very High
Juvenile Chronic Polyarthritis 88 90.72 High High
Dermatomyositis 1 73.48 Quite High
Arthritis 26 72.72 Quite High
Disease 33 50.12 Quite High
Cancer 5 50.00 Quite Low
Necrosis 4 50.00 Quite Low
Pain 31 17.52 Low Low
Fatigue 15 15.28 Low Low
Infection 24 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
There was no difference in the MTX dose or plasma MTX level between responders (15 cases) and nonresponders (seven cases) or between those with (15 cases) and without (seven cases) elevated serum transaminase levels.
Neg (no) Positive_regulation (elevated) of Gene_expression (dose) of MTX in plasma associated with methotrexate
1) Confidence 0.42 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 0.59 Pain Relevance 1.15
Bearing all these aspects in mind, we focused on the analysis of subgroups that appeared more homogeneous on both clinical and trial design grounds: previous exposure and response to DMARDs, mainly MTX, dose of anti-TNF?
Positive_regulation (response) of Gene_expression (dose) of MTX associated with methotrexate
2) Confidence 0.14 Published 2008 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2377247 Disease Relevance 0 Pain Relevance 0.19
mg plus MTX in the RAPID 1 trial (data not shown), and by patients in both CZP plus MTX groups in RAPID 2 (data not shown for CZP 400?
Positive_regulation (plus) of Gene_expression (groups) of MTX
3) Confidence 0.07 Published 2011 Journal Rheumatology (Oxford, England) Section Body Doc Link PMC3021948 Disease Relevance 0.38 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox